With more than seven million users on the HotCopper forums, every discussion and speculation can move Australian markets – which is why getting out in front of those trends is so important for any trader worth their salt.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
In this daily HotCopper Trends column, we break down the top three stocks talked about on any given trade day, and why they’ve drawn a daily focus.
First up is PolyNovo (ASX:PNV), which requested a trading halt early on Monday to navigate a news report out of the U.S. suggesting its lower-cost products may benefit from the U.S. govt’s health insurance crackdown.
PolyNovo was directly named in an article in The Australian, which said the company was increasingly confident it was going to make a pretty penny.
The halt was because PNV is also reportedly in early talks with a U.S. distributor.
4DMedical (AXS:4DX) is the next top-trender on HotCopper forums today, and while there was no mainstream media article to bump it, it’s a U.S. thematic too.
For this one, 4DMedical has been jetting across the discussion boards today after its ventilation-perfusion product, CT:VQ – billed as the world’s first CT-based VQ imaging technology – was handed FDA clearance.
And finally, Dreadnought Resources (ASX:DRE) caught attention with a new Star of Mangaroon update: The explorer had another sixteen assays return this week, all with shallow, thick, high-grade intercepts.
DRE stocks jumped +25% on Monday’s reports.
For the wider ASX, the bourse is down -0.6% mid-arvo.
That’s Monday’s HotCopper Market Trends, I’m Isaac McIntyre – see you for close.
Join the discussion: See what’s trending right now on Australia’s largest stock forum and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.